CKI-7
CKI-7 性质
熔点 | 188-190°C |
---|---|
沸点 | 499.7±55.0 °C(Predicted) |
密度 | 1.432±0.06 g/cm3(Predicted) |
储存条件 | −20°C |
溶解度 | H2O:9 mg/mL |
形态 | 固体 |
酸度系数(pKa) | 7.80±0.50(Predicted) |
颜色 | 白色 |
CKI-7 用途与合成方法
CK1 6 μM (IC 50 ) |
CK1 8.5 μM (Ki) |
Cdc7
|
SGK
|
S6K1
|
MSK1
|
CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner.
CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling.
RT-PCR
Cell Line: | Mouse ES cells |
Concentration: | 0.1-10 μM |
Incubation Time: | 5 days |
Result: | Significantly increased the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner. |
Western Blot Analysis
Cell Line: | Mouse ES cells |
Concentration: | 5 μM |
Incubation Time: | 5 days |
Result: | Suppressed SFEB-induced β-catenin stabilization on day 5. |
In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilzing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death.
CKI-7 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-133028 | CKI-7 | 120615-25-0 | 5mg | 850 |
2024-11-08 | HY-133028 | CKI-7 | 120615-25-0 | 10mg | 1500 |